Literature DB >> 3203061

Ketanserin concentration-effect relationships in individual hypertensive patients.

R Donnelly1, H L Elliott, P A Meredith, D M Hughes, J L Reid.   

Abstract

1. This study further investigates the relationship between ketanserin concentration and the fall in BP in individual hypertensive patients. 2. An integrated kinetic-dynamic model was used to characterise the response to ketanserin for each individual in terms of BP reduction per unit drug concentration and to describe the temporal discrepancy for the plasma concentration-effect relationship (keq). 3. Using the linear effect model ketanserin concentrations were well correlated with the fall in BP in individual patients. There was a significant reduction in the responsiveness to ketanserin (m) after 1 month: -0.25 mm Hg ng-1 ml-1, compared with -0.47 following the 1st dose. 4. There was a significant increase in keq from 0.49 (1st dose) to 1.86 h-1 (1 month). 5. There was no relationship between the responsiveness to ketanserin and patient age, starting BP or peripheral alpha-adrenoceptor blockade.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3203061      PMCID: PMC1386500          DOI: 10.1111/j.1365-2125.1988.tb03364.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

1.  Acute blood-pressure-lowering effect of ketanserin.

Authors:  J De Cree; H Verhaegen; J Symoens
Journal:  Lancet       Date:  1981-05-23       Impact factor: 79.321

Review 2.  Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

Authors:  N H Holford; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

3.  Acute and chronic ketanserin in essential hypertension: antihypertensive mechanisms and pharmacokinetics.

Authors:  R Donnelly; H L Elliott; P A Meredith; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1987-11       Impact factor: 4.335

4.  Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors.

Authors:  J M Van Nueten; P A Janssen; J Van Beek; R Xhonneux; T J Verbeuren; P M Vanhoutte
Journal:  J Pharmacol Exp Ther       Date:  1981-07       Impact factor: 4.030

5.  Pharmacokinetics of ketanserin in patients with essential hypertension.

Authors:  B Persson; A Pettersson; T Hedner
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

6.  A comparative and long-term evaluation of ketanserin in the treatment of essential hypertension.

Authors:  T Hedner; B Persson; G Berglund
Journal:  J Cardiovasc Pharmacol       Date:  1985       Impact factor: 3.105

7.  Haemodynamic and humoral responses to chronic ketanserin treatment in essential hypertension.

Authors:  R Fagard; R Fiocchi; P Lijnen; J Staessen; E Moerman; A de Schaepdryver; A Amery
Journal:  Br Heart J       Date:  1984-02

8.  Blood pressure reduction and pharmacokinetics of ketanserin in hypertensive patients.

Authors:  T Hedner; A Pettersson; B Persson
Journal:  J Hypertens Suppl       Date:  1986-04

9.  Ketanserin in essential hypertension: use as monotherapy and in combination with a diuretic or beta-adrenoceptor antagonist.

Authors:  H A Cameron; P C Waller; L E Ramsay
Journal:  Br J Clin Pharmacol       Date:  1987-12       Impact factor: 4.335

10.  Comparison of ketanserin and slow-release nifedipine added to the treatment of hypertensive patients uncontrolled by a thiazide diuretic plus beta-adrenoceptor blocker.

Authors:  P C Waller; S A Solomon; L E Ramsay
Journal:  Br J Clin Pharmacol       Date:  1987-11       Impact factor: 4.335

View more
  5 in total

Review 1.  Clinical pharmacokinetics of ketanserin.

Authors:  B Persson; J Heykants; T Hedner
Journal:  Clin Pharmacokinet       Date:  1991-04       Impact factor: 6.447

2.  The description and prediction of antihypertensive drug response: an individualised approach.

Authors:  R Donnelly; P A Meredith; H L Elliott
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

Review 3.  Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

Review 4.  The use of kinetic-dynamic interactions in the evaluation of drugs.

Authors:  D B Campbell
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 5.  Pharmacokinetic-pharmacodynamic relationships of alpha-adrenoceptor antagonists.

Authors:  R Donnelly; P A Meredith; H L Elliott
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.